Literature DB >> 19588547

DNA-tumor virus entry--from plasma membrane to the nucleus.

Urs F Greber1, Daniel Puntener.   

Abstract

DNA-tumor viruses comprise enveloped and non-enveloped agents that cause malignancies in a large variety of cell types and tissues by interfering with cell cycle control and immortalization. Those DNA-tumor viruses that replicate in the nucleus use cellular mechanisms to transport their genome and newly synthesized viral proteins into the nucleus. This requires cytoplasmic transport and nuclear import of their genome. Agents that employ this strategy include adenoviruses, hepadnaviruses, herpesviruses, and likely also papillomaviruses, and polyomaviruses, but not poxviruses which replicate in the cytoplasm. Here, we discuss how DNA-tumor viruses enter cells, take advantage of cytoplasmic transport, and import their DNA genome through the nuclear pore complex into the nucleus. Remarkably, nuclear import of incoming genomes does not necessarily follow the same pathways used by the structural proteins of the viruses during the replication and assembly phases of the viral life cycle. Understanding the mechanisms of DNA nuclear import can identify new pathways of cell regulation and anti-viral therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19588547     DOI: 10.1016/j.semcdb.2009.03.014

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  15 in total

1.  Stepwise loss of fluorescent core protein V from human adenovirus during entry into cells.

Authors:  Daniel Puntener; Martin F Engelke; Zsolt Ruzsics; Sten Strunze; Corinne Wilhelm; Urs F Greber
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

2.  Circovirus transport proceeds via direct interaction of the cytoplasmic dynein IC1 subunit with the viral capsid protein.

Authors:  Jingjing Cao; Cui Lin; Huijuan Wang; Lun Wang; Niu Zhou; Yulan Jin; Min Liao; Jiyong Zhou
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

3.  Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues.

Authors:  Ping-Jie Xiao; Chengwen Li; Aaron Neumann; R Jude Samulski
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

4.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

Review 5.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

6.  The dynactin complex enhances the speed of microtubule-dependent motions of adenovirus both towards and away from the nucleus.

Authors:  Martin F Engelke; Christoph J Burckhardt; Matthias K Morf; Urs F Greber
Journal:  Viruses       Date:  2011-03-09       Impact factor: 5.818

7.  The salivary secretome of the tsetse fly Glossina pallidipes (Diptera: Glossinidae) infected by salivary gland hypertrophy virus.

Authors:  Henry M Kariithi; Ikbal A Ince; Sjef Boeren; Adly M M Abd-Alla; Andrew G Parker; Serap Aksoy; Just M Vlak; Monique M van Oers
Journal:  PLoS Negl Trop Dis       Date:  2011-11-22

Review 8.  Misdelivery at the Nuclear Pore Complex-Stopping a Virus Dead in Its Tracks.

Authors:  Justin W Flatt; Urs F Greber
Journal:  Cells       Date:  2015-07-28       Impact factor: 6.600

Review 9.  The role of chromatin in adenoviral vector function.

Authors:  Carmen M Wong; Emily R McFall; Joseph K Burns; Robin J Parks
Journal:  Viruses       Date:  2013-06-14       Impact factor: 5.048

Review 10.  Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking.

Authors:  Eva Bilkova; Jitka Forstova; Levon Abrahamyan
Journal:  Viruses       Date:  2014-07-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.